Register Login

EYEPOINT, INC. (EYPT)

(10% Negative) EYEPOINT, INC. (EYPT) Announces Delay in achieved Trials for wet AMD Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 17, 2026, 12:56 p.m.

    📋 EYEPOINT, INC. (EYPT) - Clinical Trial Update

    Filing Date: 2026-08-17

    Accepted: 2026-08-17 08:50:21

    Event Type: Clinical Trial Update

    Event Details:

    EYEPOINT, INC. (EYPT) Announces Clinical Trial Update EYEPOINT, INC. (EYPT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: achieved, trial
    • Diseases/Conditions: wet AMD, full dataset
    • Clinical Stage: Phase 3, Clinical Trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: EyePoint
    • Updated Timeline: Q4 2026
      • anticipated in the fourth quarter of 2027
      • expected in Q4 2026
      • planned for 1H 2027

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: EYEPOINT, INC.
    • Ticker Symbol: EYPT

Search

News categories